Corrigendum on “Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer” [Cancer Lett. 363 (1) (2015) 28–36](S0304383515002256)(10.1016/j.canlet.2015.03.033);Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer

Cancer Letters

Volumn 363, Issue 1, 2015, Pages 28-36

  Manu, Kanjoormana A ^a   Shanmugam, Muthu K ^a   Ramachandran, Lalitha ^a   Li, Feng ^a   Siveen, Kodappully Sivaraman ^a   Chinnathambi, Arunachalam ^b   Zayed, M E ^b   Alharbi, Sulaiman Ali ^b   Arfuso, Frank ^c   Kumar, Alan Prem ^a,c,d,e   Ahn, Kwang Seok ^f   Sethi, Gautam ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c CURTIN UNIVERSITY   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF NORTH TEXAS   (United States)

^f Kyung Hee University   (South Korea)

Author keywords

Capecitabine; Gastric cancer; Isorhamnetin; NF B

Indexed keywords

CAPECITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISORHAMNETIN; TUMOR MARKER; 3-METHYLQUERCETIN; ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA; FLUOROURACIL; QUERCETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE PRODUCT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MTT ASSAY; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; STOMACH CANCER; SUBCUTANEOUS TISSUE TUMOR; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BINDING SITE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME; TUMOR CELL LINE; TUMOR VOLUME;

MUS MUSCULUS;

ANGIOGENIC PROTEINS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; NF-KAPPA B; QUERCETIN; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929044594     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2018.01.003     Document Type: Erratum

References (34)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin 2010, 60:277-300.
3. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol 2006, 24:2903-2909.
4. Kim H.K., Choi I.J., Kim C.G., Kim H.S., Oshima A., Michalowski A., et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS ONE 2011, 6. e16694.
5. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 2010, 1805:167-180.
6. Manu K.A., Shanmugam M.K., Li F., Chen L., Siveen K.S., Ahn K.S., et al. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J. Mol. Med. (Berl.) 2014, 92:267-276.
7. Manu K.A., Shanmugam M.K., Ramachandran L., Li F., Fong C.W., Kumar A.P., et al. First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway. Clin. Cancer Res 2012, 18:2220-2229.
8. Sethi G., Sung B., Aggarwal B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 2008, 233:21-31.
9. Sethi G., Tergaonkar V. Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol. Sci 2009, 30:313-321.
10. Nam S.Y., Ko Y.S., Jung J., Yoon J., Kim Y.H., Choi Y.J., et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. Br. J. Cancer 2011, 104:166-174.
11. Chao X., Zao J., Xiao-Yi G., Li-Jun M., Tao S. Blocking of PI3K/AKT induces apoptosis by its effect on NF-kappaB activity in gastric carcinoma cell line SGC7901. Biomed. Pharmacother 2010, 64:600-604.
12. Shuai X.M., Han G.X., Wang G.B., Chen J.H. Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells. World J. Gastroenterol 2006, 12:1766-1769.
13. Schimanski C.C., Galle P.R., Moehler M. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J. Gastroenterol 2008, 14:4721-4724.
14. Park E.S., Do I.G., Park C.K., Kang W.K., Noh J.H., Sohn T.S., et al. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin. Cancer Res 2009, 15:291-298.
15. Maeda S., Yoshida H., Ogura K., Mitsuno Y., Hirata Y., Yamaji Y., et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 2000, 119:97-108.
16. Yang Y.J., Chuang C.C., Yang H.B., Lu C.C., Sheu B.S. Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFkappaB pathways. BMC Microbiol 2012, 12:38.
17. Hatz R.A., Rieder G., Stolte M., Bayerdorffer E., Meimarakis G., Schildberg F.W., et al. Pattern of adhesion molecule expression on vascular endothelium in Helicobacter pylori-associated antral gastritis. Gastroenterology 1997, 112:1908-1919.
18. Long Y.M., Ye S., Rong J., Xie W.R. Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma. World J. Gastroenterol 2008, 14:4739-4744.
19. Ramachandran L., Manu K.A., Shanmugam M.K., Li F., Siveen K.S., Vali S., et al. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor gamma activation pathway in gastric cancer. J. Biol. Chem 2012, 287:38028-38040.
20. Jaramillo S., Lopez S., Varela L.M., Rodriguez-Arcos R., Jimenez A., Abia R., et al. The flavonol isorhamnetin exhibits cytotoxic effects on human colon cancer cells. J. Agric. Food Chem 2010, 58:10869-10875.
21. Kim J.E., Lee D.E., Lee K.W., Son J.E., Seo S.K., Li J., et al. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev. Res. (Phila.) 2011, 4:582-591.
22. Lee H.J., Lee E.O., Ko S.G., Bae H.S., Kim C.H., Ahn K.S., et al. Mitochondria-cytochrome C-caspase-9 cascade mediates isorhamnetin-induced apoptosis. Cancer Lett 2008, 270:342-353.
23. Choi K.C., Chung W.T., Kwon J.K., Yu J.Y., Jang Y.S., Park S.M., et al. Inhibitory effects of quercetin on aflatoxin B1-induced hepatic damage in mice. Food Chem. Toxicol 2010, 48:2747-2753.
24. Teng B.S., Lu Y.H., Wang Z.T., Tao X.Y., Wei D.Z. In vitro anti-tumor activity of isorhamnetin isolated from Hippophae rhamnoides L. against BEL-7402 cells. Pharmacol. Res 2006, 54:186-194.
25. Saud S.M., Young M.R., Jones-Hall Y.L., Ileva L., Evbuomwan M.O., Wise J., et al. Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and beta-catenin. Cancer Res 2013, 73:5473-5484.
26. Shi C., Fan L.Y., Cai Z., Liu Y.Y., Yang C.L. Cellular stress response in Eca-109 cells inhibits apoptosis during early exposure to isorhamnetin. Neoplasma 2012, 59:361-369.
27. Bao M., Lou Y. Isorhamnetin prevent endothelial cell injuries from oxidized LDL via activation of p38MAPK. Eur. J. Pharmacol 2006, 547:22-30.
28. Hamalainen M., Nieminen R., Vuorela P., Heinonen M., Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007, 2007. 45673.
29. Yang J.H., Kim S.C., Shin B.Y., Jin S.H., Jo M.J., Jegal K.H., et al. O-Methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF-kappaB activation. Food Chem. Toxicol 2013, 59:362-372.
30. Zhang N., Pei F., Wei H., Zhang T., Yang C., Ma G. Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury. Exp. Toxicol. Pathol 2011, 63:33-38.
31. Li C., Yang X., Chen C., Cai S., Hu J. Isorhamnetin suppresses colon cancer cell growth through the PI3KAktmTOR pathway. Mol. Med. Rep 2014, 9:935-940.
32. Sethi G., Ahn K.S., Sung B., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBalpha kinase activation. Biochem. Pharmacol 2008, 76:1404-1416.
33. Prakobwong S., Gupta S.C., Kim J.H., Sung B., Pinlaor P., Hiraku Y., et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 2011, 32:1372-1380.
34. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.